X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $87.74 | -7,500 | 97,994 | -7% | -$658,040 | |||||
| D | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $87.70 | -8,334 | 0 | -100% | -$730,896 | |||||
2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $87.69 | -15,000 | 582,540 | -3% | -$1,315,346 | ||||||
| M | 2026-06-30 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $21.85 | -201,050 | 620,267 | -24% | -$4,393,024 | |||||
| DM | 2026-06-30 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Chief Technical Officer | S - Sale+OE | $7.08 | -23,465 | 86,380 | -21% | -$166,131 | |||||
2026-06-30 | STTK | Shattuck Labs, Inc. | Pandite Arundathy N. | Chief Medical Officer | S - Sale | $7.01 | -30,000 | 136,219 | -18% | -$210,300 | ||||||
| M | 2026-06-30 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.50 | +107,463 | 2,641,308 | +4% | +$268,880 | |||||
| D | 2026-07-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $29.59 | -27,000 | 115,743 | -19% | -$798,908 | |||||
2026-06-30 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $70.00 | -5,681 | 9,756 | -37% | -$397,670 | ||||||
| D | 2026-06-30 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Dir | S - Sale+OE | $34.90 | -10,000 | 42,963 | -19% | -$349,000 | |||||
| M | 2026-06-30 | INM | Inmed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% | P - Purchase | $1.55 | +6,551 | 797,530 | +1% | +$10,148 | |||||
| D | 2026-07-01 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.36 | -3,333 | 96,412 | -3% | -$114,528 | |||||
| M | 2026-07-01 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $34.71 | -4,800 | 88,840 | -5% | -$166,586 | |||||
| M | 2026-07-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $71.97 | +1,712 | 506,712 | 0% | +$123,220 | |||||
| D | 2026-07-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.56 | -11,008 | 13,579 | -45% | -$259,366 | |||||
2026-07-01 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale | $120.00 | -2,721 | 3,114 | -47% | -$326,520 | ||||||
| D | 2026-07-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $554.61 | -9,500 | 668,728 | -1% | -$5,268,781 | |||||
| DM | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $15.99 | -37,179 | 145,312 | -20% | -$594,578 | |||||
| D | 2026-07-01 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $39.41 | -200,000 | 24,555 | -89% | -$7,881,402 | |||||
2026-07-01 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $84.92 | -7,500 | 381,996 | -2% | -$636,900 | ||||||
| D | 2026-07-01 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $85.80 | -15,000 | 58,555 | -20% | -$1,287,000 | |||||
| D | 2026-07-01 | CYTK | Cytokinetics Inc | Lee Sung | EVP, CFO | S - Sale+OE | $87.79 | -1,112 | 63,221 | -2% | -$97,622 | |||||
| D | 2026-07-01 | ORMP | Oramed Pharmaceuticals Inc. | Hexter Joshua | COO, CBO | S - Sale+OE | $4.46 | -137,000 | 1,073,384 | -11% | -$611,431 | |||||
2026-07-01 | ORMP | Oramed Pharmaceuticals Inc. | Gabay Avraham | CFO | S - Sale | $4.51 | -73,360 | 671,785 | -10% | -$330,744 | ||||||
| D | 2026-06-30 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale+OE | $46.42 | -30,000 | 148,235 | -17% | -$1,392,600 | |||||
| D | 2026-06-30 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $46.44 | -21,167 | 25,996 | -45% | -$983,030 | |||||
2026-06-30 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $45.50 | -115,844 | 2,555,877 | -4% | -$5,270,902 | ||||||
2026-06-30 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $45.50 | -115,844 | 2,555,877 | -4% | -$5,270,902 | ||||||
2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.03 | -90,000 | 1,716,126 | -5% | -$722,511 | ||||||
2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $8.03 | -16,666 | 1,161,128 | -1% | -$133,860 | ||||||
2026-07-01 | GNLX | Genelux Corp | Smither John W | Dir | S - Sale | $2.91 | -12,000 | 91,403 | -12% | -$34,898 | ||||||
| D | 2026-07-02 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $552.56 | -8,300 | 45,172 | -16% | -$4,586,275 | |||||
| D | 2026-07-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $543.66 | -9,500 | 668,728 | -1% | -$5,164,789 | |||||
2026-06-30 | ABEO | Abeona Therapeutics Inc. | Alland Leila | Dir | S - Sale | $5.92 | -11,000 | 162,614 | -6% | -$65,087 | ||||||
2026-07-01 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $55.88 | -9,099 | 19,020 | -32% | -$508,454 | ||||||
2026-07-01 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $20.03 | -47,775 | 2,877,118 | -2% | -$956,933 | ||||||
2026-06-30 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $56.50 | -130,000 | 499,399 | -21% | -$7,345,471 | ||||||
| D | 2026-06-30 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -4,654 | 51,776 | -8% | -$93,080 | |||||
2026-06-30 | LEGN | Legend Biotech Corp | Casey Patrick John | Dir | S - Sale | $14.80 | -6,000 | 48,604 | -11% | -$88,800 | ||||||
| D | 2026-07-01 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $37.56 | -4,007 | 84,645 | -5% | -$150,503 | |||||
2026-07-01 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.04 | +240,000 | 117,777,232 | 0% | +$10,344 | ||||||
2026-07-01 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.30 | +3,959 | 82,556 | +5% | +$13,065 | ||||||
2026-07-01 | EBS | Emergent Biosolutions Inc. | Williams Paul Anthony | SVP, Products Business | S - Sale | $8.40 | -3,000 | 159,098 | -2% | -$25,200 | ||||||
2026-06-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | COB, CEO, 10% | S - Sale | $3.03 | -7,400 | 298,589 | -2% | -$22,422 | ||||||
| D | 2026-07-01 | ORKA | Oruka Therapeutics, Inc. | Fairmount Funds Management LLC | Dir, 10% | S - Sale+OE | $84.43 | -3,553,410 | 3,705,262 | -49% | -$300,014,406 | |||||
| M | 2026-06-29 | FTH | Faeth Therapeutics, Inc. | Stephenson Brian C | CFO | P - Purchase | $23.92 | +13,634 | 46,688 | +41% | +$326,127 | |||||
| D | 2026-07-01 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale+OE | $94.42 | -5,000 | 236,384 | -2% | -$472,079 | |||||
| M | 2026-06-29 | TBPH | Theravance Biopharma, Inc. | Samaha Eli | 10% | S - Sale | $17.20 | -336,697 | 9,174,453 | -4% | -$5,791,555 | |||||
| D | 2026-07-01 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $240.25 | -49,666 | 7,351,729 | -1% | -$11,932,257 | |||||
| M | 2026-06-29 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.40 | +32,591 | 78,597 | +71% | +$110,694 | |||||
| M | 2026-06-29 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Dir | S - Sale | $35.41 | -37,600 | 315,167 | -11% | -$1,331,496 | |||||
| D | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $16.02 | -10,833 | 8,961 | -55% | -$173,590 | |||||
| D | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.01 | -10,000 | 17,217 | -37% | -$160,080 | |||||
| DM | 2026-06-29 | PHVS | Pharvaris N.V. | Lesage Anne | Chief Early Development | S - Sale+OE | $35.39 | -76,172 | 152,719 | -33% | -$2,695,452 | |||||
| D | 2026-06-29 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale+OE | $34.38 | -17,750 | 16,474 | -52% | -$610,252 | |||||
| D | 2026-07-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $51.51 | -9,000 | 73,389 | -11% | -$463,621 | |||||
| M | 2026-06-29 | PGEN | Precigen, Inc. | Thomasian Harry Jr. | CFO | S - Sale | $5.57 | -200,000 | 354,535 | -36% | -$1,113,143 | |||||
| D | 2026-06-29 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale+OE | $5.85 | -42,924 | 497,751 | -8% | -$251,105 | |||||
| D | 2026-06-29 | PGEN | Precigen, Inc. | Sabzevari Helen | Pres, CEO | S - Sale+OE | $5.89 | -346,836 | 3,768,872 | -8% | -$2,042,864 | |||||
2026-06-29 | AKBA | Akebia Therapeutics, Inc. | Ostrowski Erik | SVP, CFO, CBO, Treasurer | S - Sale | $1.11 | -56,019 | 616,616 | -8% | -$62,181 | ||||||
| D | 2026-06-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $541.00 | -9,500 | 668,728 | -1% | -$5,139,542 | |||||
| D | 2026-06-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $123.51 | -5,500 | 58,117 | -9% | -$679,305 | |||||
| DM | 2026-06-29 | BIOA | Bioage Labs, Inc. | Barton Shane | Principal Accounting Officer | S - Sale+OE | $25.20 | -62,566 | 0 | -100% | -$1,576,752 | |||||
| D | 2026-06-30 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $18.53 | -7,026 | 1,203,784 | -1% | -$130,220 | |||||
2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $1.93 | +2,436 | 14,727 | +20% | +$4,701 | ||||||
2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $1.93 | +2,106 | 14,853 | +17% | +$4,065 | ||||||
2026-07-01 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $1.93 | +3,057 | 19,780 | +18% | +$5,900 | ||||||
2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $1.93 | +3,277 | 16,689 | +24% | +$6,325 | ||||||
2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $1.93 | +2,531 | 24,412 | +12% | +$4,885 | ||||||
2026-06-30 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale | $41.58 | -10,000 | 149,914 | -6% | -$415,798 | ||||||
2026-06-29 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $39.83 | -8,220 | 650,485 | -1% | -$327,398 | ||||||
2026-06-30 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $18.32 | +50,000 | 3,295,897 | +2% | +$916,000 | ||||||
2026-06-30 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $20.00 | +12,500 | 3,688,424 | 0% | +$250,000 | ||||||
2026-06-29 | ADIL | Adial Pharmaceuticals, Inc. | Coastlands Capital LP | 10% | P - Purchase | $2.60 | +25,000 | 373,322 | +7% | +$65,000 | ||||||
| M | 2026-06-26 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $34.46 | -1,638,163 | 15,437,569 | -10% | -$56,444,076 | |||||
| M | 2026-06-26 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $34.32 | -1,438,163 | 13,689,166 | -10% | -$49,354,076 | |||||
| M | 2026-06-26 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $34.32 | -1,438,163 | 13,689,166 | -10% | -$49,354,076 | |||||
| D | 2026-06-29 | CLYM | Climb Bio, Inc. | Brennan Aoife | Pres, CEO | S - Sale+OE | $13.17 | -30,902 | 87,731 | -26% | -$406,979 | |||||
| DM | 2026-06-26 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | Dir | S - Sale+OE | $5.03 | -30,000 | 6,500 | -82% | -$150,891 | |||||
| DM | 2026-06-26 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $5.04 | -52,037 | 0 | -100% | -$262,084 | |||||
| M | 2026-06-26 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $21.23 | -504,695 | 983,893 | -34% | -$10,712,550 | |||||
| D | 2026-06-29 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $35.18 | -2,178 | 793 | -73% | -$76,622 | |||||
2026-06-30 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $26.14 | -75,000 | 614,321 | -11% | -$1,960,601 | ||||||
| D | 2026-06-26 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $25.90 | -104,124 | 38,400 | -73% | -$2,696,322 | |||||
| DM | 2026-06-26 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $75.00 | -2,500 | 52,173 | -5% | -$187,500 | |||||
| D | 2026-06-26 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $80.16 | -5,635 | 53,191 | -10% | -$451,699 | |||||
2026-06-26 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale | $80.00 | -3,069 | 61,470 | -5% | -$245,520 | ||||||
| D | 2026-06-26 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale+OE | $81.05 | -26,000 | 77,114 | -25% | -$2,107,196 | |||||
| D | 2026-06-26 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $72.50 | -300 | 54,324 | -1% | -$21,750 | |||||
| D | 2026-06-26 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $85.26 | -8,130 | 62,874 | -11% | -$693,151 | |||||
2026-06-26 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale | $46.86 | -1,434 | 168,235 | -1% | -$67,197 | ||||||
| D | 2026-06-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $545.80 | -9,500 | 668,728 | -1% | -$5,185,133 | |||||
2026-06-26 | FULC | Fulcrum Therapeutics, Inc. | Ezekowitz Alan | Dir | S - Sale | $3.65 | -18,000 | 10,927 | -62% | -$65,614 | ||||||
2026-06-29 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $84.12 | -2,850 | 177,543 | -2% | -$239,742 | ||||||
2026-06-26 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $482.50 | -596 | 15,337 | -4% | -$287,570 | ||||||
2026-06-26 | PRQR | Proqr Therapeutics N.V. | Filius Bart | Dir | P - Purchase | $1.54 | +150,000 | 150,000 | New | +$231,000 | ||||||
2026-06-25 | LEGN | Legend Biotech Corp | Huang Ying | CEO | S - Sale | $14.78 | -5,566 | 241,872 | -2% | -$82,265 | ||||||
| D | 2026-06-25 | CAPR | Capricor Therapeutics, Inc. | Krasney Karen | EVP, GC | S - Sale+OE | $30.38 | -24,100 | 30,547 | -44% | -$732,158 | |||||
| D | 2026-06-25 | CAPR | Capricor Therapeutics, Inc. | Bergmann Anthony | CFO | S - Sale+OE | $30.38 | -24,100 | 11,223 | -68% | -$732,158 | |||||
| M | 2026-06-25 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.50 | +286,333 | 2,533,845 | +13% | +$714,768 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |